A further meeting, sponsored by WHO, was held on 4-8 December 1995 in Geneva. The
purpose was to review in great detail the latest scientific evidence for, and practical …

Over recent years many antimalarial drugs have been rendered useless by the development
of resistance by the malaria parasite. New antimalarials are rapidly suffering the same fate …

Participants in both consultations Dr CJ Canfield, Pharmaceutical Systems Incorporated,
Gaithersburg, Maryland, United States of America.

The enzymic and non-enzymic formation of protein-arylating intermediates from
amodiaquine (AQ, 7-chloro-4-(3'-diethylamino-4'-hydroxyanilino) quinoline), an anti-malarial …

A method is described for the simultaneous determination of amodiaquine (AQ) and
desethylamodiaquine (AQm) in plasma, urine, whole blood and packed red cells. After oral …

Life threatening hypoglycaemia has been closely associated with the use of quinine, but the
effect of quinidine and the synthetic antimalarials on the homoeostasis of glucose has not …

Seven patients developed hepatitis after receiving amodiaquine for malaria prophylaxis for 4
to 15 weeks. Four patients had a minor form of hepatitis: jaundice was mild or absent, serum …

A specific enzyme-linked immunosorbent assay (ELISA) was developed for the detection
and characterisation of antibodies directed against amodiaquine (AQ), an anti-malarial drug …

In the last ten years, the widespread increase in Plasmodium falciparum resistance to
chloroquine has prompted research into antimalarial 4‐aminoquinolines, empirically used …

Quinine dihydrochloride (10 mg or, in two patients, a loading dose of 20 mg kg‐1) was
infused intravenously over 4 h in ten severely ill but conscious women with falciparum …